NASDAQ:ZLAB Zai Lab Q3 2026 Earnings Date & Estimates $24.84 +0.03 (+0.10%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Zai Lab is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Zai Lab in Q3 2026Zai Lab is expected to post earnings of -$0.56 per share on revenue of $108.84 million. In the same quarter a year earlier Zai Lab reported -$0.33 per share on revenue of $116.10 million. Zai Lab last reported on August 6, 2026, posting -$0.46 per share and beating the -$0.68 consensus estimate. Zai Lab has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.56Expected Revenue$108.84 millionPrior-Year EPS-$0.33Prior-Year Revenue$116.10 millionExpected Revenue Growth-6.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.46 (Beat by +$0.22)Last Quarter Revenue$106.31 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Zai Lab Q3 2026 Earnings FAQ When does Zai Lab report Q3 2026 earnings? Zai Lab (NASDAQ:ZLAB) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Zai Lab's Q3 2026 earnings call? Zai Lab's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Zai Lab? Analysts expect Zai Lab to post earnings of -$0.56 per share for Q3 2026. How much revenue is Zai Lab expected to report? The consensus revenue estimate for Zai Lab is $108.84 million for Q3 2026. Zai Lab Earnings HeadlinesCritical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)October 7 at 5:15 AM | americanbankingnews.comIs Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?October 4, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 9 at 1:00 AM | InvestorPlace (Ad)Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)September 29, 2026 | marketscreener.comMZai Lab Ltd (ZLAB)September 24, 2026 | in.investing.comZai Lab Limited (ZLAB)September 11, 2026 | finance.yahoo.comSee More Zai Lab Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zai Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zai Lab and other key companies, straight to your email. Email Address About Zai LabZai Lab (NASDAQ:ZLAB) Ltd. (NASDAQ: ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases with significant unmet medical needs. The company’s research and development activities span oncology, autoimmune and inflammatory disorders, infectious diseases, and neuroscience. Founded in 2014 by Samantha Du, Zai Lab has built a portfolio through internal research as well as licensing and collaboration agreements with international pharmaceutical and biotechnology companies. Its products and partnered therapies have included treatments such as ZEJULA (niraparib) for certain ovarian cancers, QINLOCK (ripretinib) for gastrointestinal stromal tumors, and NUZYRA (omadacycline), an antibiotic used to treat certain bacterial infections. Zai Lab has historically concentrated on developing and commercializing innovative therapies in China while expanding its research, development and commercial capabilities internationally. The company’s operations have included activities in China, the United States and other global markets, supported by partnerships intended to broaden access to its medicines. Zai Lab was founded and led by Samantha Du, a biotechnology executive with experience in drug development and company building.View Zai Lab ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Applied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadJetBlue's LaGuardia Win Could Change Its Financial FutureConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now? Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
